title: Oral tolvaptan is safe and effective in chronic hyponatremia.
abstract: Vasopressin antagonists increase the serum sodium concentration in patients who have euvolemia and hypervolemia with hyponatremia in the short term (</=30 days), but their safety and efficacy with longer term administration is unknown. SALTWATER was a multicenter, open-label extension of the Study of Ascending Levels of Tolvaptan in Hyponatremia (SALT-1 and SALT-2). In total, 111 patients with hyponatremia received oral tolvaptan for a mean follow-up of 701 days, providing 77,369 patient-days of exposure. All patients had hyponatremia at randomization in SALT-1 and SALT-2, and 85% continued to have hyponatremia at entry in SALTWATER. The most common adverse effects attributed to tolvaptan were pollakiuria, thirst, fatigue, dry mouth, polydipsia, and polyuria. Six drug-related adverse effects led to study discontinuation. The increase in serum sodium exceeded the desired 1 mmol/L per h at initiation in five patients. Hypernatremia (>145 mmol/L) led to discontinuation in one patient. Mean serum sodium increased from 130.8 mmol/L at baseline to >135 mmol/L throughout the observation period (P < 0.001 versus baseline at most points). Responses were comparable between patients with euvolemia and those with heart failure but more modest in patients with cirrhosis. In conclusion, prolonged administration of tolvaptan maintains an increased serum sodium with an acceptable margin of safety.
authors.affiliation: University of Colorado Denver, Division of Renal Diseases and Hypertension, Aurora, CO 80045, USA. tomas.berl@ucdenver.edu
authors.forename: Tomas
authors.initials: T
authors.lastname: Berl
authors.forename: Friederike
authors.initials: F
authors.lastname: Quittnat-Pelletier
authors.forename: Joseph G
authors.initials: JG
authors.lastname: Verbalis
authors.forename: Robert W
authors.initials: RW
authors.lastname: Schrier
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Bichet
authors.forename: John
authors.initials: J
authors.lastname: Ouyang
authors.forename: Frank S
authors.initials: FS
authors.lastname: Czerwiec
mesh_terms: D000284:Administration, Oral; D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000008:administration & dosage*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000077602:Tolvaptan
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D000077602:Tolvaptan